Table 1.
Median OS times of NSCLC patients according to the expression of ALDH1A1, ALDH1A3 and ALDH3A1.
| Median overall survival (months) | |||||
|---|---|---|---|---|---|
| Gene expression | NSCLC nontreated with neoadjuvant therapy (N = 241) | NSCLC treated with chemotherapy (N = 90) | Grade I (N = 201) | Grade II (N = 310) | Grade III (N = 77) |
| ALDH1A1Low | 75 | 53.3 | 32.6 | 62 | 77.6 |
| ALDH1A1High | 95 (P = 0.130) | 37 (P = 0.160) | 79 (P = 0.001) | 36 (P = 0.062) | 32 (P = 0.064) |
| ALDH1A3Low | 106 | 62 | 74 | 78.9 | 75.7 |
| ALDH1A3High | 68 (P = 0.005) | 36 (P = 0.031) | 48 (P = 0.139) | 44.4 (P = 0.0522) | 56.8 (P = 0.280) |
| ALDH3A1Low | 96 | 77.6 | 68.6 | 96.1 | 65 |
| ALDH3A1High | 70.6 (P = 0.032) | 32 (P = 0.005) | 52 (P = 0.282) | 65.2 (P = 0.062) | 26.9 (P = 0.05) |